Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2016			2015		2014
Antibiotic	$	14,558		$	12,306	$	13,572
Cardiovascular	53,541			55,166		62,121
Central Nervous System	36,291			—		—
Gallstone	67,348			65,262		6,578
Gastrointestinal	52,699			—		—
Glaucoma	25,336			21,145		11,987
Gout	303			6,833		10,822
Migraine	21,776			25,729		14,527
Muscle Relaxant	5,403			8,779		—
Obesity	3,809			4,004		4,032
Pain Management	29,804			27,461		27,174
Respiratory	9,982			—		—
Thyroid Deficiency	162,411			153,460		102,248
Urinary	17,398			212		—
Other	43,389			26,480		20,710
Contract manufacturing revenue	22,043			—		—
Net sales	566,091			406,837		273,771
Settlement agreement	(23,598		)	—		—
Total net sales	$	542,493		$	406,837	$	273,771

Summary of products which accounted for at least 10% of net sales

	June 30, 2016		June 30, 2015		June 30, 2014
Product 1	30	%	38	%	37	%
Product 2	12	%	16	%	2	%
Product 3	4	%	12	%	20	%

Summary of customers which accounted for at least 10% of net sales

	June 30, 2016		June 30, 2015		June 30, 2014
Customer A	25	%	30	%	19	%
Customer B	16	%	11	%	8	%
Customer C	—	%	—	%	13	%